As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time NEW DELHI : Aurobindo Pharma on Tuesday said the US health regulator has decided that the inspection classification of company's injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI).
As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement